<span item_type="fundamental" item_id="3b8812d2f2332135256ec8872788d94b" counter_id="ST/US/CBRRF" env="prod"></span><span item_type="announcement" item_id="549442447433666561" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD 0.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -305.28 K.</p><p></p><h3>Segment Revenue</h3><ul><li>The company did not generate any operating revenues during the period as it is a blank check company focused on effecting a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income (Loss)</strong>: For the three months ended June 30, 2025, net income was approximately $5,800, compared to a net loss of approximately $448,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li><li><strong>General and Administrative Expenses</strong>: For the three months ended June 30, 2025, general and administrative expenses were approximately $275,000, compared to $563,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li><li><strong>Change in Fair Value of Derivative Liabilities</strong>: Gain of approximately $242,000 for the three months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended June 30, 2025, net cash used in operating activities was approximately - $273,548.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li><li><strong>Net Cash Provided by (Used in) Financing Activities</strong>: For the six months ended June 30, 2025, net cash provided by financing activities was approximately $174,150.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Investment Income on Trust Account</strong>: For the three months ended June 30, 2025, investment income was approximately $56,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company has until November 15, 2025, to consummate an initial Business Combination. If not completed by this date, the company must cease operations, redeem public shares, and liquidate.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li><li><strong>Non-Core Business</strong>: The company is focused on completing a business combination with Phytanix Bio, which is expected to close within the SEC’s prescribed timeline.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li><li><strong>Priority</strong>: The company is committed to ensuring compliance with the Investment Company Act and the updated SEC guidance, aiming to mitigate risks associated with the potential application of the Investment Company Act.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1845149/000121390025076601/ea0252787-10q_chain1.htm"></span></li></ul>

CHAIN BRIDGE I | 10-Q: FY2025 Q2 EPS: USD 0